2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      State of the Art in Respiratory Syncytial Virus Drug Discovery and Development

      1 , 1 , 1
      Journal of Medicinal Chemistry
      American Chemical Society (ACS)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Respiratory syncytial virus (RSV) is a globally prevalent viral infection with limited treatment options which hospitalizes millions each year. Treatment options have been limited to palivizumab, a monoclonal antibody, approved for prophylaxis in high-risk infants and ribavirin with very limited efficacy and significant safety concerns. This Perspective surveys the range of direct acting antiviral agents (DAAs) that target key steps in the viral life cycle. A number of approaches to DAAs have produced landmark clinical studies over the past few years, notably in fusion and nucleoside inhibitors, and an update of the clinical status of these compounds is provided. Non-nucleoside inhibitors of replication are reviewed in addition to inhibitors of other mechanisms, notably the RSV N and G proteins. This article will provide an informative perspective of the current status of drug discovery targeted at providing an effective therapy for RSV infection.

          Related collections

          Author and article information

          Journal
          Journal of Medicinal Chemistry
          J. Med. Chem.
          American Chemical Society (ACS)
          0022-2623
          1520-4804
          November 21 2018
          November 21 2018
          Affiliations
          [1 ]ReViral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, United Kingdom
          Article
          10.1021/acs.jmedchem.8b01361
          30411898
          4a647053-cc95-409d-9b99-4fa436c5008c
          © 2018
          History

          Comments

          Comment on this article